

SAVE
THE
DATE

April 16, 17 2026
INSTITUT CURIE
PARIS
FRANCE

AN INTERNATIONAL COURSE
THE PATHOLOGY OF MELANOMA



Directed by:



Director of course
Pr Raymond Barnhill
• Paris, France



Pr Boris Bastian
• San Francisco, USA



Pr Klaus Busam
• New York, USA



Pr David Elder
• Philadelphia, USA



Pr Richard Scolyer
• Sydney, Australia

OBJECTIVES

Following the success of our Courses in 2017, 2018, 2020, 2022, and 2024 the objectives of the Sixth International Melanoma Course in 2026 will continue to stress due diligence and practical diagnosis of melanocytic lesions. We will emphasize the theme of **“Acknowledging uncertainty and avoiding over diagnosis of melanoma”**, as well as **updates of all cutting-edge knowledge on difficult melanocytic lesions relevant to practicing pathologists and clinicians.**

This 2026 venue will again include expertise from the SIRIC (Integrated Cancer Research Site at Institut Curie), the final WHO 5th Edition Classification of Melanocytic Tumours, the revised and updated MPATH-Dx Classification schema (2023), the MPATH Group, and the International Melanoma Pathology Study Group.



LANGUAGE
CONGRESS:
ENGLISH



April 16, 17 2026

THE PATHOLOGY OF MELANOMA

AN INTERNATIONAL COURSE

INSTITUT CURIE

AMPHITHEATER CONSTANT BURG

PARIS FRANCE



THE REVISED UPDATED MPATH-Dx CLASSIFICATION

- The revised and updated MPATH (Version 2.0) schema provides a simplified two category system for benign melanocytic lesions: Class I. Low-grade and Class II. High-grade lesions. Practical criteria allow for the mapping of all benign melanocytic lesions with diverse terminologies into these categories.
- The classification of melanoma is refined by the recognition of a low-risk category of T1a melanoma in the new Class III.
- The schema provides estimates of risk for disease progression and guidelines for practical management.

THE COURSE PROGRAM AND CONTENT

- The Course will consist of didactic lectures and interactive sessions during the two-day program.
- An approach of practical diagnosis is based on the extensive experience of the international faculty in the Course.
- The latest advances in ancillary diagnostic techniques including immunohistochemistry and molecular genetics will be emphasized.
- Particular attention will be given to predictive biomarkers for targeted, immune and checkpoint inhibitors therapies.

More information : www.melanoma-course.com



Caroline Métais
Garance Events
+33 6 21 15 16 83

caroline.metais@garance-events.com